Maruyama Shigeo, Matono Tomomitsu, Koda Masahiko
Maruyama Medical Clinic, Aioimacho 3921, Hamada 697-0034, Shimane, Japan.
St. Mary's Hospital, Nibuno 650, Himeji 670-0801, Hyogo, Japan.
J Clin Med. 2022 Jul 26;11(15):4347. doi: 10.3390/jcm11154347.
Background: Knowledge of the relationships between hepatic hemangiomas and coagulopathy and the risk factors for hemangiomas is lacking. The aim of this study was to investigate the prevalence and characteristics of hepatic hemangiomas associated with coagulopathy, elucidate the causes of coagulopathy, and identify the predictive factors for hemangioma-related complications. Methods: In 281 consecutive patients with hepatic hemangiomas, we performed ultrasonography and conducted serum laboratory tests for liver function and six coagulation factors, i.e., platelets, as well as five coagulation fibrinolytic markers (prothrombin time (PT), fibrinogen, thrombin-antithrombin III complex (TAT), d-dimer, and fibrin and fibrinogen degradation products (FDP)) as indicators of coagulation disorder. Results: Among 281 patients, 56 (19.9%) had abnormal coagulation factors. Abnormal values of d-dimer were most frequently found among the six coagulation factors. The number of abnormal coagulation factors was significantly correlated with tumor size, M2BPGi, and HDL cholesterol, among which tumor size was the most significant independent predictor of the number of abnormal coagulation factors. Conclusions: The prevalence of hepatic hemangiomas associated with coagulopathy was relatively high and became more frequent with increases in tumor size. Predictive factors of hemangioma-related complications were found to be a tumor size of >5 cm in diameter and coagulopathy, especially the elevation of d-dimer.
目前尚缺乏关于肝血管瘤与凝血病之间的关系以及血管瘤危险因素的认识。本研究的目的是调查与凝血病相关的肝血管瘤的患病率和特征,阐明凝血病的病因,并确定血管瘤相关并发症的预测因素。方法:在连续281例肝血管瘤患者中,我们进行了超声检查,并对肝功能和六种凝血因子进行了血清实验室检测,即血小板,以及五种凝血纤溶标志物(凝血酶原时间(PT)、纤维蛋白原、凝血酶 - 抗凝血酶III复合物(TAT)、D - 二聚体和纤维蛋白及纤维蛋白原降解产物(FDP))作为凝血障碍的指标。结果:在281例患者中,56例(19.9%)凝血因子异常。在六种凝血因子中,D - 二聚体异常值最常见。凝血因子异常数量与肿瘤大小、M2BPGi和高密度脂蛋白胆固醇显著相关,其中肿瘤大小是凝血因子异常数量最显著的独立预测因素。结论:与凝血病相关的肝血管瘤患病率相对较高,且随肿瘤大小增加而更常见。发现血管瘤相关并发症的预测因素是直径>5 cm的肿瘤大小和凝血病,尤其是D - 二聚体升高。